Faster revenue growth seen for molecular IVD tests

NEW YORK -- Tests aimed at molecular targets for use in clinical decision-making will produce much faster revenue growth than traditional in vitro diagnostic (IVD) tests, according to Kalorama Information. 

Kalorama Information said tests are a USD5.2-billion dollar and will grow 8% each year to 7.6 billion by 2017. That's four times as fast as revenue growth in standard chemistry tests and twice as fast as immunoassay markets, according to the company's IVD market research database. The finding was made in its recent report, "The World Market for Molecular Diagnostics, 5^th Edition".

The continued discovery of genetic markers with proven clinical utility and the increasing adoption of genetic based diagnostic tests are driving usage. The most attractive growth areas are molecular tests for histological analyses, women's health, infectious diseases, organ transplant testing and oncology. New tests are being launched all the time. Many molecular tests are CE Marked and FDA-cleared and many more are in development.

"These are exciting times for molecular diagnostics," said Shara Rosen, Kalorama Information's lead analyst and author of the report. "It represents one of the fastest growing segments of the diagnostics market. It has emerged fully from research into clinical practice."

Instrumentation now automates many of the sample preparation and asAir Max 2017